Cangrelor, sold under the brand name Kengreal among others, is a P2Y 12 inhibitor FDA approved as of June 2015 as an antiplatelet drug [5] for intravenous application.

Explore KENGREAL® (cangrelor) for high-risk or complex PCI, including clinical data, use cases, dosing and resources. See Full Prescribing and Important Safety Information.

Easy-to-read patient leaflet for Cangrelor. Includes indications, proper use, special instructions, precautions, and possible side effects.

Medscape - Acute coronary syndrome dosing for Kengreal (cangrelor), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost...

Cangrelor (Kengreal) is a drug used to reduce the risk of heart attacks during percutaneous coronary intervention, repeat coronary revascularization, and stent thrombosis.

Feb 1, 2026 · Cangrelor injection is used in patients undergoing percutaneous coronary intervention (PCI) to lower the risk of blood clots and heart attack. A heart attack or stroke may occur when a …

Cangrelor is the only currently available intravenous platelet P2Y 12 receptor inhibitor. It is characterized by potent, predictable, and rapidly reversible antiplatelet effects.

Cangrelor is a direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent...

Cangrelor Injection What is this medication? CANGRELOR (KAN grel or) lowers the risk of heart attack, stroke, or blood clots. It prevents blood cells (platelets) from clumping together to form a clot. It …

Jul 2, 2021 · Cangrelor is the only currently available intravenous platelet P2Y 12 receptor inhibitor. It is characterized by potent, predictable, and rapidly reversible antiplatelet effects.